190 related articles for article (PubMed ID: 32875599)
1. CD33-Targeted Therapies: Beating the Disease or Beaten to Death?
Maakaron JE; Rogosheske J; Long M; Bachanova V; Mims AS
J Clin Pharmacol; 2021 Jan; 61(1):7-17. PubMed ID: 32875599
[TBL] [Abstract][Full Text] [Related]
2. Investigational CD33-targeted therapeutics for acute myeloid leukemia.
Walter RB
Expert Opin Investig Drugs; 2018 Apr; 27(4):339-348. PubMed ID: 29534618
[TBL] [Abstract][Full Text] [Related]
3. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
4. The role of CD33 as therapeutic target in acute myeloid leukemia.
Walter RB
Expert Opin Ther Targets; 2014 Jul; 18(7):715-8. PubMed ID: 24750020
[TBL] [Abstract][Full Text] [Related]
5. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
6. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
7. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
Kung Sutherland MS; Walter RB; Jeffrey SC; Burke PJ; Yu C; Kostner H; Stone I; Ryan MC; Sussman D; Lyon RP; Zeng W; Harrington KH; Klussman K; Westendorf L; Meyer D; Bernstein ID; Senter PD; Benjamin DR; Drachman JG; McEarchern JA
Blood; 2013 Aug; 122(8):1455-63. PubMed ID: 23770776
[TBL] [Abstract][Full Text] [Related]
8. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Xu Q; He S; Yu L
Front Immunol; 2021; 12():683595. PubMed ID: 34484181
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia.
Hibma J; Knight B
Clin Pharmacokinet; 2019 Mar; 58(3):335-347. PubMed ID: 30062662
[TBL] [Abstract][Full Text] [Related]
10. Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
Gottardi M; Sperotto A; Ghelli Luserna Di Rorà A; Padella A; Cangini D; Giannini MB; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):395-410. PubMed ID: 32955828
[TBL] [Abstract][Full Text] [Related]
11. The past and future of CD33 as therapeutic target in acute myeloid leukemia.
Laszlo GS; Estey EH; Walter RB
Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/Pharmacodynamic Modeling to Support the Re-approval of Gemtuzumab Ozogamicin.
Fostvedt LK; Hibma JE; Masters JC; Vandendries E; Ruiz-Garcia A
Clin Pharmacol Ther; 2019 Nov; 106(5):1006-1017. PubMed ID: 31070776
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
[TBL] [Abstract][Full Text] [Related]
14. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
15. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
16. The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
Ali S; Dunmore HM; Karres D; Hay JL; Salmonsson T; Gisselbrecht C; Sarac SB; Bjerrum OW; Hovgaard D; Barbachano Y; Nagercoil N; Pignatti F
Oncologist; 2019 May; 24(5):e171-e179. PubMed ID: 30898889
[TBL] [Abstract][Full Text] [Related]
17. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Radiographic Response of Extramedullary Leukemia in Patients Treated With Gemtuzumab Ozogamicin.
McNeil MJ; Parisi MT; Hijiya N; Meshinchi S; Cooper T; Tarlock K
J Pediatr Hematol Oncol; 2019 Apr; 41(3):e174-e176. PubMed ID: 29734213
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
Stein EM; Walter RB; Erba HP; Fathi AT; Advani AS; Lancet JE; Ravandi F; Kovacsovics T; DeAngelo DJ; Bixby D; Faderl S; Jillella AP; Ho PA; O'Meara MM; Zhao B; Biddle-Snead C; Stein AS
Blood; 2018 Jan; 131(4):387-396. PubMed ID: 29196412
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab ozogamicin for acute myeloid leukemia.
Appelbaum FR; Bernstein ID
Blood; 2017 Nov; 130(22):2373-2376. PubMed ID: 29021230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
